MVC-101
mAbexperimentalBi-specific
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 8, 2021 (NCT04844073)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04891718 | Early Phase 1 (Phase 1) | Oct 31, 2021 | Presage Biosciences, Takeda |
| NCT04844073 | Phase 1/Phase 2 (Phase 2) | Mar 8, 2021 | Takeda |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 2 | 1 | 2 | 2021 |
| Presage Biosciences | For profit | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1